Mounjaro Evidence Base Graded by GRADE: What the Trials Actually Show for Women

What GRADE Actually Means and Why It Matters for This Drug

GRADE (Grading of Recommendations Assessment, Development and Evaluation) rates bodies of evidence as HIGH, MODERATE, LOW, or VERY LOW based on risk of bias, inconsistency, indirectness, imprecision, and publication bias. GRADE Working Group methods are described here. A HIGH rating means further research is very unlikely to change confidence in the effect estimate. A VERY LOW rating means any effect estimate is highly uncertain.

For tirzepatide, the GRADE exercise produces a split verdict: the glycemic data are strong, the weight data are promising but younger, and data in women-specific conditions are thin to absent.

Why GRADE ratings for women may be lower than the headline number

Most SURPASS trials enrolled patients with type 2 diabetes who were predominantly middle-aged adults of both sexes. Women made up roughly 46-52% of SURPASS trial participants, but sex-disaggregated subgroup analyses were not the primary endpoint in any SURPASS publication. When evidence is generated in a mixed population and then applied to women specifically, the GRADE framework calls this "indirectness," which drops the rating by one level. For conditions that are female-exclusive or female-predominant (PCOS, perimenopause-related weight gain, postpartum metabolic dysfunction), the indirectness penalty may drop evidence to LOW or VERY LOW.

This is an honest limitation, not a reason to dismiss the drug. It is a reason to read the sex-specific data carefully, which is exactly what this article does.

SURPASS-2: The Key Head-to-Head Against Semaglutide

SURPASS-2 is the trial most relevant for clinical decision-making. It was a 40-week, open-label, randomized trial comparing tirzepatide 5 mg, 10 mg, and 15 mg against semaglutide 1 mg subcutaneous weekly in 1,879 adults with type 2 diabetes inadequately controlled on metformin. Results were published in the New England Journal of Medicine in 2021.

Primary endpoint: A1C reduction

Tirzepatide outperformed semaglutide 1 mg at every dose tested:

| Tirzepatide dose | Mean A1C reduction | vs. Semaglutide 1 mg (1.86%) | |---|---|---| | 5 mg | 1.94% | Non-inferior | | 10 mg | 2.20% | Superior (p <0.001) | | 15 mg | 2.46% | Superior (p <0.001) |

A1C reductions at 10 mg and 15 mg were statistically and clinically superior to semaglutide 1 mg. GRADE rating for this endpoint: HIGH. The trial was large, well-conducted, and the effect was consistent across pre-specified subgroups.

Secondary endpoint: Body weight

Mean body weight reduction at week 40:

• Tirzepatide 5 mg: 7.6 kg
• Tirzepatide 10 mg: 9.3 kg
• Tirzepatide 15 mg: 12.4 kg
• Semaglutide 1 mg: 6.2 kg

All three tirzepatide doses produced significantly greater weight loss than semaglutide 1 mg. GRADE rating for weight loss in T2D: MODERATE (open-label design, 40-week duration leaves long-term durability uncertain).

What SURPASS-2 does not tell you about women

The trial did not report outcomes separately by sex in the primary publication. Women were approximately 46% of the population. The semaglutide comparator was the 1 mg dose, not the 2.4 mg obesity dose (Wegovy), so this is not a fair weight-loss comparison against semaglutide at its highest approved dose. Women considering tirzepatide for weight management should note that SURMOUNT-1 (see below) is more relevant.

SURMOUNT-1: The Weight-Loss Trial That Applies to Most Women Asking About Mounjaro

SURMOUNT-1 enrolled 2,539 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity but without type 2 diabetes. Results were published in the New England Journal of Medicine in 2022. At 72 weeks:

• Tirzepatide 5 mg: mean 15.0% weight reduction vs 3.1% for placebo
• Tirzepatide 10 mg: mean 19.5% weight reduction
• Tirzepatide 15 mg: mean 20.9% weight reduction

These reductions represent the largest weight losses reported in any phase 3 GLP-1 class trial at the time of publication.

Sex-disaggregated data from SURMOUNT-1

Women in SURMOUNT-1 achieved meaningful but modestly smaller weight losses than men at the 15 mg dose: approximately 21.4% in women versus 24.5% in men based on subgroup data reported in the supplementary appendix. This pattern is consistent with what has been observed across the GLP-1 class and likely reflects sex differences in adipose tissue distribution, baseline body composition (women carry proportionally more subcutaneous versus visceral fat), and possibly differences in GIP receptor density. Sex-disaggregated GLP-1 receptor agonist response has been reviewed in Obesity Reviews. The practical implication: if you are a woman who does not achieve the 5% weight loss benchmark at 12 weeks on tirzepatide 5 mg, that alone should not drive discontinuation without a conversation about dose escalation.

GRADE rating for weight loss in obesity without T2D: MODERATE (72 weeks, placebo-controlled, large sample, but questions remain about durability post-discontinuation and representativeness for women with specific hormonal drivers of weight gain).

Maintenance after stopping

SURMOUNT-4, a withdrawal trial, showed that stopping tirzepatide after 36 weeks of treatment led to partial weight regain: participants regained approximately 14 percentage points of body weight over the subsequent 52 weeks on placebo, while those continuing tirzepatide maintained loss. SURMOUNT-4 data were published in JAMA in 2024. GRADE for durability of effect after discontinuation: LOW, because weight regain is the expected outcome and the trials were not designed to study long-term strategies in women with hormonal contributors to weight.

The Rest of the SURPASS Program: A Rapid GRADE Summary

SURPASS-1 (monotherapy)

SURPASS-1 compared tirzepatide monotherapy against placebo in drug-naive T2D over 40 weeks. A1C reductions ranged from 1.87% to 2.07% across doses. GRADE: HIGH for A1C, MODERATE for weight.

SURPASS-3 (vs. Insulin degludec)

SURPASS-3 showed tirzepatide 15 mg reduced A1C by 2.37% versus 1.34% for titrated insulin degludec. For women with T2D who are on basal insulin and want to transition, this trial is particularly relevant because weight gain with insulin is a frequent concern. Tirzepatide 15 mg produced a 12.9 kg weight reduction vs a 2.3 kg gain in the insulin arm. GRADE: HIGH for A1C, MODERATE for weight.

SURPASS-5 (add-on to insulin glargine)

SURPASS-5 tested tirzepatide added to insulin glargine plus metformin. A1C reductions reached 2.11% at 15 mg. GRADE: HIGH for A1C in this setting.

SURPASS-CVOT (cardiovascular outcomes)

The SURPASS-CVOT trial (also called SURPASS-4 in some references) evaluated tirzepatide against insulin glargine in high-CV-risk T2D. Results published in The Lancet in 2022 showed a 15% non-significant reduction in MACE events with tirzepatide. The trial was not powered for CV superiority. GRADE for CV outcomes: LOW (underpowered for this endpoint). The SURMOUNT-MMO trial, a dedicated CV outcomes trial in obesity, is ongoing and will substantially change this rating when reported.

How Hormonal Status Changes the Evidence Picture for Women

This section does not have a corresponding trial to cite. It is an area where the evidence base is genuinely thin, and that matters.

Reproductive years and the menstrual cycle

GLP-1 receptors are expressed in the hypothalamus, ovary, and endometrium. Animal data and small human studies suggest GLP-1 receptor agonists may modestly alter LH pulsatility. No SURPASS or SURMOUNT trial measured cycle length, ovulation, or luteal function as outcomes. If you are in your reproductive years and your cycles change after starting tirzepatide, that signal has no controlled trial behind it yet. GRADE for menstrual effects: VERY LOW (mechanistic data only).

PCOS

PCOS affects 8-13% of women of reproductive age worldwide according to WHO. Insulin resistance and hyperinsulinemia are central to its pathophysiology, and GLP-1 receptor agonists improve both. Liraglutide 1.8 mg produced clinically meaningful improvements in menstrual regularity, androgens, and weight in small PCOS RCTs. A 2023 systematic review in Fertility and Sterility found GLP-1 RAs reduced fasting insulin, free testosterone, and BMI in PCOS. No dedicated tirzepatide PCOS RCT has been published as of this writing. Evidence is extrapolated from the GLP-1 class and from tirzepatide's metabolic mechanism. GRADE for tirzepatide in PCOS: VERY LOW (class-level extrapolation, no direct RCT).

Perimenopause and menopause

Menopause-related weight gain centers on visceral adiposity and worsening insulin sensitivity, the two metabolic phenotypes tirzepatide addresses most powerfully. The Menopause Society's 2023 position statement on weight management notes that GLP-1 receptor agonists are appropriate adjuncts for postmenopausal women with obesity. No SURPASS or SURMOUNT trial was designed for peri- or postmenopausal women specifically, and none measured vasomotor symptom frequency as an outcome. GRADE for tirzepatide in menopausal weight management: LOW (general obesity evidence applied, moderate indirectness for this population).

Postpartum metabolic dysfunction

Gestational diabetes markedly increases a woman's lifetime T2D risk. Women with prior GDM have a 7-fold higher risk of developing T2D compared to those without GDM, per a Lancet meta-analysis. Tirzepatide is not approved or studied for use in the postpartum period. Given the lactation contraindication (see below), this represents a significant evidence gap for a population that needs metabolic intervention.

Pregnancy, Lactation, and Contraception: What You Must Know Before Starting

This section is not optional reading. Tirzepatide is contraindicated in pregnancy.

Pregnancy safety data

Tirzepatide is classified as FDA Pregnancy Category not formally assigned under the new labeling system, but the FDA prescribing information states that tirzepatide caused fetal harm in animal studies at exposures below the maximum recommended human dose. In rat studies, tirzepatide produced skeletal malformations and embryo-fetal mortality at doses producing exposures 0.4 times the 15 mg human weekly dose. No adequate human pregnancy data exist. The mechanism of concern is shared with all GLP-1 receptor agonists: caloric restriction during organogenesis and potential direct receptor-mediated effects on fetal tissues.

If you become pregnant while on tirzepatide, stop the drug immediately and contact your clinician.

ACOG recommends against using GLP-1 receptor agonists during pregnancy pending adequate safety data. Women who are trying to conceive should discontinue tirzepatide before attempting pregnancy. The prescribing label recommends stopping at least two months before a planned pregnancy based on the drug's half-life of approximately five days (five half-lives = approximately 35 days, but a two-month margin adds buffer for tissue clearance).

Contraception requirements

Because tirzepatide slows gastric emptying, oral contraceptive pill absorption may be reduced for the first four weeks after starting tirzepatide or after each dose escalation. The prescribing information recommends switching to a non-oral contraceptive method or adding a barrier method for four weeks after initiation and for four weeks after each dose increase. Long-acting reversible contraception (IUD, implant) is not affected by this interaction and is the most reliable option for women on tirzepatide who want to avoid pregnancy.

Lactation

Tirzepatide is present in rat milk. No human lactation data exist. The FDA label advises against use during breastfeeding due to the potential for serious adverse reactions in the nursing infant. The LactMed database has not established safety. GRADE for lactation safety: VERY LOW (animal data only, no human PK data in breast milk).

Who This Drug Is Right For (and Who Should Wait)

Life-stage by life-stage breakdown

Reproductive years, not trying to conceive: Tirzepatide is a reasonable option for T2D or obesity with a comorbidity. Use reliable non-oral contraception or add a barrier method for four weeks at each dose step. If PCOS is driving the metabolic picture, tirzepatide may offer benefits beyond glucose and weight, but you are working with extrapolated evidence and should frame expectations accordingly.

Trying to conceive: Stop tirzepatide at least two months before attempting conception. If insulin resistance is driving ovulatory dysfunction in PCOS, a GLP-1 RA started well before the conception window may improve ovulatory frequency, but discontinue before attempting pregnancy.

Pregnant: Do not use. Full stop.

Postpartum and lactating: Do not use during breastfeeding. For women with prior GDM who want early postpartum metabolic intervention, the evidence gap here is real and frustrating. Lifestyle intervention and, in some cases, metformin remain the options with established postpartum safety data.

Perimenopause: A reasonable candidate if BMI and metabolic markers qualify. Consider that vasomotor symptoms and sleep disruption in perimenopause may worsen nausea (tirzepatide's most common side effect, reported in 17-22% of participants across SURMOUNT-1 dose groups). Start at 2.5 mg and escalate slowly.

Postmenopause: Evidence from SURMOUNT-1 applies with moderate indirectness. For postmenopausal women on hormone therapy, no pharmacokinetic interaction with estrogen or progesterone formulations has been reported in the prescribing information.

Who should not start tirzepatide

• Personal or family history of medullary thyroid carcinoma or MEN2 (black box contraindication)
• Pregnancy or planned pregnancy within two months
• Active breastfeeding
• Severe gastroparesis (drug worsens gastric motility)
• History of pancreatitis (avoid; the association remains debated but the label carries a warning)

Side Effects: The Female-Specific Signal

Nausea is the most common reason women discontinue GLP-1 and dual GIP/GLP-1 agonists. Across SURPASS-2, nausea occurred in 17.5% of tirzepatide 15 mg users vs 9.9% with semaglutide 1 mg. Women report nausea from GLP-1 receptor agonists at higher rates than men across the class, likely because estrogen sensitizes the area postrema (the brain's nausea center) and because gastric emptying is already slower in women at baseline. Baseline gastric emptying time in healthy women is approximately 20-30% longer than in men.

Practical management: take tirzepatide on the same day each week, eat small low-fat meals for the first 48 hours after each injection, and escalate dose no faster than every eight weeks (the label allows four weeks minimum; slower escalation reduces GI dropout).

Muscle mass loss is a concern with any significant weight loss. Women lose proportionally more lean mass during caloric deficit than men because of lower baseline muscle mass and the anabolic role of testosterone. SURMOUNT-1 did not report body composition by DXA as a primary outcome. Resistance training and adequate protein intake (at least 1.2 g/kg/day) should be explicitly discussed when prescribing tirzepatide to women.

Hair thinning (telogen effluvium) is reported anecdotally and in post-marketing data for GLP-1 receptor agonists during rapid weight loss phases, though no prospective trial has quantified its incidence in women specifically. GRADE for this adverse effect in women: VERY LOW.

Evidence Gaps the Next Trials Need to Fill

A practical framework for rating what is known vs what is extrapolated for women specifically:

| Clinical question | GRADE rating | Key gap | |---|---|---| | A1C reduction in T2D | HIGH | None major | | Weight loss in obesity without T2D | MODERATE | Long-term durability, rebound on discontinuation | | CV outcomes | LOW | SURMOUNT-MMO ongoing | | Weight loss in perimenopause/menopause | LOW | No dedicated trial | | PCOS metabolic and reproductive outcomes | VERY LOW | No tirzepatide RCT | | Menstrual cycle effects | VERY LOW | No trial measured this | | Postpartum metabolic use | VERY LOW | Excluded from trials; lactation concern | | Muscle mass preservation in women | VERY LOW | No DXA primary outcome in SURMOUNT-1 | | Pregnancy safety | VERY LOW (harm signal in animals) | No human data; contraindicated |

The honest answer is that tirzepatide's evidence base is strongest for the endpoints that were powered: A1C and weight in mixed-sex adult populations. For the conditions most specific to women's physiology, the evidence is thinner than the marketing suggests, and clinicians should communicate that clearly.

Dosing Reference for Women Starting Tirzepatide

The approved starting dose is 2.5 mg subcutaneous once weekly for four weeks, then 5 mg once weekly. The prescribing information permits escalation in 2.5 mg steps no sooner than every four weeks, up to a maximum of 15 mg weekly. For women with significant GI sensitivity (common in perimenopause, PCOS, and those with functional GI disorders), a longer step duration of eight weeks at each dose is clinically reasonable and reduces discontinuation.

The American Diabetes Association 2024 Standards of Care recommend GLP-1 receptor agonists and dual GIP/GLP-1 agonists as preferred agents for T2D in patients with obesity or high CV risk. Tirzepatide is named explicitly as a dual GIP/GLP-1 agent with the highest glycemic and weight efficacy in the class.

For women using oral contraceptives: switch to a patch, ring, IUD, or implant before starting tirzepatide, or add a barrier method for four weeks at initiation and after each dose escalation. This is the recommendation in the FDA-approved label and should be discussed at the prescribing visit, not left to the pharmacy leaflet.